| 2024 |
| 01/18 | 3,350 | 3,350 | 3,320 | 3,325 | -0.6% | 25,100 | 1280億1250万 | +0.57% |
| 01/17 | 3,380 | 3,410 | 3,345 | 3,345 | -1.04% | 36,300 | 1287億8250万 | +1.27% |
| 01/16 | 3,420 | 3,430 | 3,370 | 3,380 | -0.88% | 22,300 | 1301億3000万 | +2.3% |
| 01/15 | 3,380 | 3,420 | 3,370 | 3,410 | +1.49% | 23,500 | 1312億8500万 | +3.18% |
| 01/12 | 3,415 | 3,415 | 3,350 | 3,360 | -1.18% | 24,700 | 1293億6000万 | +1.76% |
| 01/11 | （自社株買い）取締役会(2023年5月15日)での決議状況(取得期間2023年5月16日～2024年3月22日) |
| 01/11 | 3,400 | 3,410 | 3,375 | 3,400 | +0.29% | 31,100 | 1309億 | +2.94% |
| 01/10 | 3,375 | 3,405 | 3,330 | 3,390 | +1.04% | 38,200 | 1305億1500万 | +2.7% |
| 01/09 | 3,310 | 3,365 | 3,310 | 3,355 | +1.36% | 26,800 | 1291億6750万 | +1.67% |
| 01/05 | 3,330 | 3,335 | 3,295 | 3,310 | -0.45% | 21,000 | 1274億3500万 | +0.27% |
| 01/04 | （IR情報）14:00 自己株式の取得状況に関するお知らせ |
| 01/04 | 3,270 | 3,325 | 3,230 | 3,325 | +1.68% | 33,600 | 1280億1250万 | +0.64% |
| 2023 |
| 12/29 | 3,295 | 3,295 | 3,260 | 3,270 | -0.46% | 15,800 | 1258億9500万 | -1.03% |
| 12/28 | 3,290 | 3,290 | 3,250 | 3,285 | +0.46% | 17,400 | 1264億7250万 | -0.64% |
| 12/27 | 3,225 | 3,275 | 3,225 | 3,270 | +0.77% | 29,100 | 1258億9500万 | -1.09% |
| 12/26 | 3,255 | 3,270 | 3,235 | 3,245 | +0.15% | 29,400 | 1249億3250万 | -1.82% |
| 12/25 | 3,260 | 3,270 | 3,230 | 3,240 | -1.37% | 21,000 | 1247億4000万 | -1.91% |
| 12/22 | 3,265 | 3,290 | 3,260 | 3,285 | +1.39% | 18,100 | 1264億7250万 | -0.54% |
| 12/21 | 3,245 | 3,260 | 3,240 | 3,240 | -0.46% | 18,400 | 1247億4000万 | -1.79% |
| 12/20 | 3,225 | 3,270 | 3,225 | 3,255 | +0.77% | 21,100 | 1253億1750万 | -1.36% |
| 12/19 | 3,265 | 3,270 | 3,215 | 3,230 | -0.92% | 24,800 | 1243億5500万 | -2.15% |
| 12/18 | 3,245 | 3,265 | 3,215 | 3,260 | +0.15% | 26,200 | 1255億1000万 | -1.3% |
| 12/15 | 3,330 | 3,330 | 3,255 | 3,255 | -1.66% | 44,000 | 1253億1750万 | -1.51% |
| 12/14 | 3,335 | 3,335 | 3,290 | 3,310 | +0.3% | 21,600 | 1274億3500万 | +0.09% |
| 12/13 | 3,295 | 3,325 | 3,280 | 3,300 | +0.15% | 16,900 | 1270億5000万 | -0.24% |
| 12/12 | （自社株買い）取締役会(2023年5月15日)での決議状況(取得期間2023年5月16日～2024年3月22日) |
| 12/12 | 3,330 | 3,340 | 3,290 | 3,295 | -0.15% | 14,900 | 1268億5750万 | -0.39% |
| 12/11 | 3,280 | 3,315 | 3,280 | 3,300 | +0.92% | 25,600 | 1270億5000万 | -0.3% |
| 12/08 | 3,315 | 3,330 | 3,250 | 3,270 | -2.39% | 43,900 | 1258億9500万 | -1.24% |
| 12/07 | 3,390 | 3,395 | 3,345 | 3,350 | -1.76% | 24,400 | 1289億7500万 | +1.03% |
| 12/06 | 3,380 | 3,425 | 3,365 | 3,410 | +1.79% | 69,000 | 1312億8500万 | +2.9% |
| 12/05 | 3,345 | 3,380 | 3,345 | 3,350 | -0.45% | 29,500 | 1289億7500万 | +1.33% |
| 12/04 | 3,365 | 3,375 | 3,330 | 3,365 | 0% | 28,900 | 1295億5250万 | +1.82% |
| 12/01 | （IR情報）14:00 自己株式の取得状況に関するお知らせ |
| 12/01 | 3,400 | 3,425 | 3,355 | 3,365 | +0.3% | 54,800 | 1295億5250万 | +1.97% |
| 11/30 | 3,315 | 3,355 | 3,255 | 3,355 | -0.74% | 136,200 | 1291億6750万 | +1.73% |
| 11/29 | 3,385 | 3,395 | 3,365 | 3,380 | -0.29% | 31,600 | 1301億3000万 | +2.55% |
| 11/28 | （IR情報）14:00 人事異動のお知らせ |
| 11/28 | 3,350 | 3,395 | 3,345 | 3,390 | +1.65% | 33,800 | 1305億1500万 | +2.91% |
| 11/27 | 3,340 | 3,345 | 3,315 | 3,335 | +0.91% | 27,100 | 1283億9750万 | +1.34% |
| 11/24 | 3,285 | 3,310 | 3,270 | 3,305 | +0.3% | 23,200 | 1272億4250万 | +0.49% |
| 11/22 | （IR情報）10:00 持続型G-CSF製剤「ペグフィルグラスチムBS皮下注3.6mg「モチダ」」の薬価基準収載ならびに新発売のお知らせ |
| 11/22 | 3,245 | 3,300 | 3,245 | 3,295 | +1.85% | 32,300 | 1268億5750万 | +0.24% |
| 11/21 | 3,195 | 3,240 | 3,195 | 3,235 | +1.25% | 25,800 | 1245億4750万 | -1.52% |
| 11/20 | 3,235 | 3,245 | 3,180 | 3,195 | -1.24% | 30,100 | 1230億750万 | -2.74% |
| 11/17 | 3,200 | 3,240 | 3,200 | 3,235 | +1.41% | 28,400 | 1245億4750万 | -1.61% |
| 11/16 | 3,225 | 3,260 | 3,180 | 3,190 | -2.3% | 43,200 | 1228億1500万 | -3.1% |
| 11/15 | 3,295 | 3,300 | 3,230 | 3,265 | -0.61% | 54,600 | 1257億250万 | -1.03% |
| 11/14 | 3,310 | 3,310 | 3,285 | 3,285 | 0% | 23,200 | 1264億7250万 | -0.51% |
| 11/13 | （自社株買い）取締役会(2023年5月15日)での決議状況(取得期間2023年5月16日～2024年3月22日) |
| 11/13 | 3,310 | 3,315 | 3,285 | 3,285 | -0.76% | 15,800 | 1264億7250万 | -0.58% |
| 11/10 | 3,270 | 3,315 | 3,265 | 3,310 | +0.15% | 21,200 | 1274億3500万 | +0.21% |
| 11/09 | 3,370 | 3,370 | 3,270 | 3,305 | -0.45% | 20,300 | 1272億4250万 | +0.18% |
| 11/08 | 3,300 | 3,330 | 3,280 | 3,320 | +0.61% | 26,700 | 1278億2000万 | +0.76% |
| 11/07 | 3,335 | 3,360 | 3,295 | 3,300 | -1.49% | 32,100 | 1270億5000万 | +0.18% |
| 11/06 | 3,395 | 3,400 | 3,310 | 3,350 | +0.75% | 49,300 | 1289億7500万 | +1.67% |
| 11/02 | （IR情報）14:00 2024年3月期第2四半期決算短信〔日本基準〕(連結) |
| 11/02 | 3,320 | 3,380 | 3,310 | 3,325 | -1.92% | 28,500 | 1280億1250万 | +0.88% |
| 11/01 | （IR情報）11:30 自己株式の取得状況に関するお知らせ |
| 11/01 | 3,380 | 3,395 | 3,360 | 3,390 | +2.42% | 45,100 | 1305億1500万 | +2.7% |
| 10/31 | （IR情報）15:30 不眠症治療薬ダリドレキサントの日本における製造販売承認申請のお知らせ |
| 10/31 | 3,225 | 3,320 | 3,225 | 3,310 | +3.28% | 41,100 | 1274億3500万 | +0.27% |
| 10/30 | 3,260 | 3,290 | 3,190 | 3,205 | -3.61% | 42,100 | 1233億9250万 | -3% |
| 10/27 | 3,275 | 3,325 | 3,255 | 3,325 | +2.15% | 29,500 | 1280億1250万 | +0.45% |
| 10/26 | 3,280 | 3,320 | 3,240 | 3,255 | -1.36% | 37,000 | 1253億1750万 | -1.75% |
| 10/25 | 3,310 | 3,330 | 3,300 | 3,300 | -0.3% | 17,600 | 1270億5000万 | -0.54% |
| 10/24 | 3,310 | 3,325 | 3,245 | 3,310 | -0.45% | 21,200 | 1274億3500万 | -0.42% |
| 10/23 | （IR情報）14:00 神経再生誘導材の米国における510(k)申請のお知らせ |
| 10/23 | 3,295 | 3,350 | 3,295 | 3,325 | +0.45% | 27,000 | 1280億1250万 | -0.12% |
| 10/20 | 3,280 | 3,330 | 3,280 | 3,310 | +0.61% | 19,400 | 1274億3500万 | -0.69% |
| 10/19 | 3,230 | 3,305 | 3,230 | 3,290 | +0.92% | 23,800 | 1266億6500万 | -1.38% |
| 10/18 | 3,295 | 3,295 | 3,215 | 3,260 | +0.46% | 24,300 | 1255億1000万 | -2.4% |
| 10/17 | 3,240 | 3,270 | 3,215 | 3,245 | +0.15% | 25,300 | 1249億3250万 | -2.93% |
| 10/16 | 3,215 | 3,275 | 3,210 | 3,240 | -0.92% | 27,800 | 1247億4000万 | -3.17% |
| 10/13 | 3,320 | 3,320 | 3,270 | 3,270 | -2.1% | 16,900 | 1258億9500万 | -2.42% |
| 10/12 | 3,365 | 3,365 | 3,315 | 3,340 | -0.15% | 12,800 | 1285億9000万 | -0.51% |
| 10/11 | （自社株買い）取締役会(2023年5月15日)での決議状況(取得期間2023年5月16日～2024年3月22日) |
| 10/11 | 3,375 | 3,375 | 3,330 | 3,345 | -0.3% | 24,900 | 1287億8250万 | -0.45% |
| 10/10 | 3,350 | 3,370 | 3,330 | 3,355 | +1.05% | 26,700 | 1291億6750万 | -0.21% |
| 10/06 | 3,270 | 3,340 | 3,270 | 3,320 | +1.22% | 21,900 | 1278億2000万 | -1.31% |
| 10/05 | 3,205 | 3,285 | 3,205 | 3,280 | +2.34% | 32,600 | 1262億8000万 | -2.55% |
| 10/04 | 3,200 | 3,235 | 3,175 | 3,205 | -0.16% | 25,800 | 1233億9250万 | -4.9% |
| 10/03 | 3,285 | 3,290 | 3,210 | 3,210 | -2.28% | 31,900 | 1235億8500万 | -4.89% |
| 10/02 | （IR情報）14:00 自己株式の取得状況に関するお知らせ |
| 10/02 | 3,370 | 3,370 | 3,285 | 3,285 | -1.5% | 33,200 | 1264億7250万 | -2.81% |
| 09/29 | 3,365 | 3,370 | 3,320 | 3,335 | -0.89% | 26,800 | 1283億9750万 | -1.39% |
| 09/28 | 3,380 | 3,400 | 3,345 | 3,365 | -2.6% | 29,300 | 1295億5250万 | -0.47% |
| 09/27 | 3,370 | 3,455 | 3,360 | 3,455 | +2.37% | 46,300 | 1330億1750万 | +2.28% |
| 09/26 | 3,375 | 3,410 | 3,360 | 3,375 | -0.88% | 23,600 | 1299億3750万 | +0.09% |
| 09/25 | （IR情報）15:00 持続型G-CSF製剤「ペグフィルグラスチムBS皮下注3.6mg『モチダ』/『ニプロ』」の国内における製造販売承認取得のお知らせ |
| 09/25 | 3,355 | 3,425 | 3,355 | 3,405 | +1.49% | 32,300 | 1310億9250万 | +1.1% |
| 09/22 | 3,355 | 3,370 | 3,345 | 3,355 | -0.89% | 24,700 | 1291億6750万 | -0.18% |
| 09/21 | 3,400 | 3,430 | 3,380 | 3,385 | -0.29% | 21,100 | 1303億2250万 | +0.83% |
| 09/20 | 3,435 | 3,440 | 3,385 | 3,395 | -1.16% | 31,500 | 1307億750万 | +1.19% |
| 09/19 | 3,420 | 3,445 | 3,410 | 3,435 | -0.15% | 25,500 | 1322億4750万 | +2.42% |
| 09/15 | 3,415 | 3,465 | 3,390 | 3,440 | +0.73% | 66,800 | 1324億4000万 | +2.69% |
| 09/14 | 3,390 | 3,425 | 3,375 | 3,415 | +0.29% | 22,400 | 1314億7750万 | +2.06% |
| 09/13 | 3,395 | 3,410 | 3,360 | 3,405 | +0.59% | 34,000 | 1310億9250万 | +1.95% |
| 09/12 | （自社株買い）取締役会(2023年5月15日)での決議状況(取得期間2023年5月16日～2024年3月22日) |
| 09/12 | 3,340 | 3,395 | 3,340 | 3,385 | +1.65% | 27,300 | 1303億2250万 | +1.5% |
| 09/11 | 3,330 | 3,345 | 3,295 | 3,330 | +0.6% | 35,600 | 1282億500万 | +0.09% |
| 09/08 | 3,350 | 3,370 | 3,310 | 3,310 | -2.07% | 47,800 | 1274億3500万 | -0.33% |
| 09/07 | 3,410 | 3,410 | 3,370 | 3,380 | -0.88% | 27,400 | 1301億3000万 | +1.78% |
| 09/06 | 3,415 | 3,430 | 3,395 | 3,410 | -0.15% | 21,200 | 1312億8500万 | +2.77% |
| 09/05 | 3,385 | 3,420 | 3,375 | 3,415 | +0.59% | 28,300 | 1314億7750万 | +3.02% |
| 09/04 | 3,425 | 3,425 | 3,385 | 3,395 | -0.59% | 24,100 | 1307億750万 | +2.54% |
| 09/01 | （IR情報）14:00 自己株式の取得状況に関するお知らせ |
| 09/01 | 3,375 | 3,425 | 3,375 | 3,415 | +1.19% | 35,500 | 1314億7750万 | +3.27% |
| 08/31 | 3,375 | 3,390 | 3,370 | 3,375 | +0.45% | 39,600 | 1299億3750万 | +2.24% |
| 08/30 | （IR情報）14:00 人事異動のお知らせ |
| 08/30 | （IR情報）14:00 潰瘍性大腸炎治療剤「コレチメント錠 9mg」の薬価基準収載ならびに新発売のお知らせ |
| 08/30 | 3,365 | 3,380 | 3,345 | 3,360 | +0.6% | 27,800 | 1293億6000万 | +1.91% |
| 08/29 | 3,345 | 3,365 | 3,325 | 3,340 | -0.15% | 26,400 | 1285億9000万 | +1.43% |
| 08/28 | 3,320 | 3,360 | 3,320 | 3,345 | +0.9% | 30,000 | 1287億8250万 | +1.7% |
| 08/25 | 3,300 | 3,340 | 3,300 | 3,315 | -0.15% | 29,200 | 1276億2750万 | +0.94% |
| 08/24 | 3,290 | 3,335 | 3,290 | 3,320 | +0.91% | 16,200 | 1278億2000万 | +1.25% |
| 08/23 | 3,260 | 3,295 | 3,260 | 3,290 | -0.3% | 11,700 | 1266億6500万 | +0.46% |
| 08/22 | 3,290 | 3,305 | 3,270 | 3,300 | +0.92% | 20,900 | 1270億5000万 | +0.86% |
